<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Regeneron Pharmaceuticals</strong> (NASDAQ:REGN).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with REGN, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, Benzinga's options scanner spotted 11 uncommon options trades for Regeneron Pharmaceuticals.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 36% bullish and 36%, bearish.</p>
<p>Out of all of the special options we uncovered, 7 are puts, for a total amount of $344,526, and 4 are calls, for a total amount of $458,064.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $400.0 to $800.0 for Regeneron Pharmaceuticals during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Regeneron Pharmaceuticals's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Regeneron Pharmaceuticals's substantial trades, within a strike price spectrum from $400.0 to $800.0 over the preceding 30 days.</p>
<h3>Regeneron Pharmaceuticals Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768417244_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="Options Call Chart" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768417244_0.png"/></p>

<h3>Biggest Options Spotted:</h3>
<p></p><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$128.3</td>
<td>$122.4</td>
<td>$124.5</td>
<td>$630.00</td>
<td>$311.2K</td>
<td align="right">111</td>
<td align="right">25</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.5</td>
<td>$12.7</td>
<td>$15.5</td>
<td>$775.00</td>
<td>$65.1K</td>
<td align="right">346</td>
<td align="right">42</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.2</td>
<td>$12.3</td>
<td>$15.2</td>
<td>$775.00</td>
<td>$63.8K</td>
<td align="right">346</td>
<td align="right">122</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$17.4</td>
<td>$11.4</td>
<td>$11.4</td>
<td>$775.00</td>
<td>$61.5K</td>
<td align="right">346</td>
<td align="right">302</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/16/28</td>
<td>$185.0</td>
<td>$179.5</td>
<td>$185.0</td>
<td>$800.00</td>
<td>$55.5K</td>
<td align="right">4</td>
<td align="right">3</td>
</tr>
</tbody>
</table><p></p>
<h3>About Regeneron Pharmaceuticals</h3>
<p>Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).</p>
<p>In light of the recent options history for Regeneron Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Regeneron Pharmaceuticals</h3>
<ul>
<li>Currently trading with a volume of 269,395, the REGN's price is up by 0.21%, now at $760.5. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 16 days.</li>
</ul>
<h3>What The Experts Say On Regeneron Pharmaceuticals</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $840.0.</p>
<ul>
<li>An analyst from B of A Securities has elevated its stance to Buy, setting a new price target at $860. </li>
<li>An analyst from Truist Securities has decided to maintain their Buy rating on Regeneron Pharmaceuticals, which currently sits at a price target of $820. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>

REGN

<p>Investors are showing a bullish sentiment towards Regeneron Pharmaceuticals (NASDAQ:REGN), with significant options trades indicating potential price movements between $400 and $800. Recent data reveals a split sentiment among traders, with 36% bullish and 36% bearish. The stock is currently trading at $760.5, up 0.21%, with an anticipated earnings release in 16 days. Analysts have set target prices averaging $840, with one analyst raising their target to $860. Options trading presents higher risks but also greater profit potential for serious investors.</p>

This Is What Whales Are Betting On Regeneron Pharmaceuticals